Synergistic antitumor activity of rapamycin and EF24 via increasing ROS for the treatment of gastric cancer

Mechanistic/mammalian target of rapamycin (mTOR) has emerged as a new potential therapeutic target for gastric cancer. Rapamycin and rapamycin analogs are undergoing clinical trials and have produced clinical responses in a subgroup of cancer patients. However, monotherapy with rapamycin at safe dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Weiqian, Zou, Peng, Zhao, Zhongwei, Chen, Xi, Fan, Xiaoxi, Vinothkumar, Rajamanickam, Cui, Ri, Wu, Fazong, Zhang, Qianqian, Liang, Guang, Ji, Jiansong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048112/
https://www.ncbi.nlm.nih.gov/pubmed/27697670
http://dx.doi.org/10.1016/j.redox.2016.09.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048112/
https://www.ncbi.nlm.nih.gov/pubmed/27697670
http://dx.doi.org/10.1016/j.redox.2016.09.006

Ejemplares similares